|
|
???tair.name??? >
???browser.page.title.author???
|
"ross p"???jsp.browse.items-by-author.description???
Showing items 1-5 of 5 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 國立成功大學 |
2023 |
Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial
|
Ren, Z.;Ducreux, M.;Abou-Alfa, G.K.;Merle, P.;Fang, W.;Edeline, J.;Li, Z.;Wu, L.;Assenat, E.;Hu, S.;Rimassa, L.;Zhang, T.;Blanc, J.-F.;Pan, H.;Ross, P.;Yen, C.-J.;Tran, A.;Shao, G.;Bouattour, M.;Chen, Y.;Meyer, T.;Hou, J.;Tougeron, D.;Bai, Y.;Hou, M.-M.;Meng, Z.;Wu, J.;Li, V.;Chica-Duque, S.;Cheng, A.-L. |
| 臺大學術典藏 |
2021-05-03T02:20:50Z |
First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials
|
Wasan H.S.; Gibbs P.; Sharma N.K.; Taieb J.; Heinemann V.; Ricke J.; Peeters M.; Findlay M.; Weaver A.; Mills J.; Wilson C.; Adams R.; Francis A.; Moschandreas J.; Virdee P.S.; Dutton P.; Love S.; Gebski V.; Gray A.; Bateman A.; Blesing C.; Brown E.; Chau I.; Cummins S.; Cunningham D.; Falk S.; Hadaki M.; Hall M.; Hickish T.; Hornbuckle J.; Lofts F.; Lowndes S.; Mayer A.; Metcalfe M.; Middleton G.; Montazeri A.; Muirhead R.; Polychronis A.; Purcell C.; Ross P.; Sharma R.A.; Sherwin L.; Smith D.; Soomal R.; Swinson D.; Walther A.; Wilson G.; Amin P.; Angelelli B.; Balosso J.; Beny A.; Bloomgarden D.; Boucher E.; Bruch H.-R.; Bui J.; Burge M.; Cardaci G.; Carlisle J.; Chai S.; Chen Y.-J.; Chevallier P.; Chuong M.; Clarke S.; Coveler A.; Craninx M.; Delanoit T.; Deleporte A.; Eliadis P.; Facchini F.; Ferguson T.; Ferrante M.; Frenette G.; Frick J.; Ganju V.; Garofalo M.; Geboes K.; Gehbauer G.; George B.; Geva R.; Gordon M.; Gregory K.; Gulec S.; Hannigan J.; van Hazel G.; Heching N.; Helmberger T.; Hendlisz A.; Hendrickx K.; Holtzman M.; Isaacs R.; Jackson C.; James P.; Kaiser A.; Karapetis C.; Kaubisch A.; Ko Y.-D.; Kr?ning H.; Lammert F.; Liauw W.; Limentani S.; Louafi S.; de Man M.; Margolis J.; Martin R.; Martoni A.; Marx G.; Matos M.; Monsaert E.; Moons V.; Nott L.; Nusch A.; O'Donnell A.; Ozer H.; Padia S.; Pavlakis N.; Perez D.; Pluntke S.; Polus M.; Powell A.; Pracht M.; Price T.; Ransom D.; Rebischung C.; Ridwelski K.; Riera-Knorrenschild J.; Riess H.; Rilling W.; Robinson B.; Rodr?guez J.; Sanchez F.; Sauerbruch T.; Savin M.; Scheidhauer K.; Schneiderman E.; Seeger G.; Segelov E.; Schmueli E.S.; Shani A.; Shannon J.; Shibata S.; Singhal N.; Smith D.; Smith R.; Stemmer S.; St?tzer O.; Strickland A.; Tatsch K.; Terrebonne E.; Tichler T.; Vehling-Kaiser U.; Vera-Garcia R.; Vogl T.; Walpole E.; Wang E.; Whiting S.; Wolf I.; Ades S.; Aghmesheh M.; Auber M.; Ayala H.; Boland P.; Bouche E.; Bowers C.; Bremer C.; Casado A.R.; Cooray P.; Crain M.; De Wit M.; Dowling K.; Durand A.; Faivre S.; Feeney K.; Ferru A.; Fragoso M.; Granetto C.; Hammel P.; Issacs R.; Iyer R.; Kim Y.H.; JIN-TUNG LIANG; Lim L.; Liu J.H.; Masi G.; Mosconi S.; Numico G.; Ratner L.; Sae-Won H.; Singh M.; Stoltzfus P.; Tan I.; Trogu A.; Underhill C.; Westcott M.; FOXFIRE trial investigators, SIRFLOX trial investigators, FOXFIRE-Global trial investigators, SIRFLOX trial investigators, FOXFIRE-Global trial investigators, FOXFIRE-Global trial investigators |
| 國立成功大學 |
2018 |
Phase II studies with refametinib or refametinib plus sorafenib in patients with RAS-mutated hepatocellular Carcinoma
|
Lim, H.Y.;Merle, P.;Weiss, K.H.;Yau, T.;Ross, P.;Mazzaferro, V.;Blanc, J.-F.;Ma, Y.T.;Yen, C.J.;Kocsis, J.;Choo, S.P.;Sukeepaisarnjaroen, W.;Gerolami, R.;Dufour, J.-F.;Gane, E.J.;Ryoo, B.-Y.;Peck-Radosavljevic, M.;Dao, T.;Yeo, W.;Lamlertthon, W.;Thongsawat, S.;Teufel, M.;Roth, K.;Reis, D.;Childs, B.H.;Krissel, H.;Llovet, J.M. |
| 國家衛生研究院 |
2016-06 |
Safety across subgroups in NAPOLI-1: A phase 3 study of nal-IRI (MM-398) +/- 5-fluorouracil and leucovorin (5-FU/LV) versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
|
Chen, LT;Siveke, J;Wang-Gillam, A;Hubner, R;Pant, S;Dragovich, T;Chung, V;Chang, D;Ross, P;Cooray, P;Tebbutt, N;Franke, F;Belanger, B;Dhindsa, N;de Jong, F;Mamlouk, K;Von Hoff, D |
| 國立成功大學 |
2015-06-01 |
Combined analysis of two randomised Phase II trials comparing the efficacy and safety of nintedanib versus sorafenib in Caucasian and Asian patients with advanced hepatocellular carcinoma
|
Palmer, D.; Meyer, T.; Chao, Y.; Deptala, A.; Fartoux, L.; Feng, Y. -H.; Graham, J.; Lin, D. -Y.; Ma, Y. T.; Peck-Radosavljevic, M.; Ross, P.; Ryoo, B. -Y.; Yen, C. -J.; Hocke, J.; Vlassak, S.; Wenz, A.; Loembe, A. -B.; Cheng, A. -L. |
Showing items 1-5 of 5 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
